ArticleFrontiers in cardiovascular medicine2026
Case Report: Managing a patent foramen ovale complicated by severe left-sided heart failure and multiple thromboembolic events.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The management of patent foramen ovale (PFO) in patients with concurrent severe left-sided heart failure (HF) and a high burden of pulmonary thromboembolism poses a therapeutic dilemma. This case report describes a tailored strategy that prioritizes left atrial unloading in such a complex scenario. Case presentation: We present the case of a 31-year-old man with ischemic cardiomyopathy (left ventricular ejection fraction 30%-35%) and a history of multiple thromboembolic events. Extensive evaluation revealed a PFO with a left-to-right shunt, chronically elevated left atrial pressure (LAP), a massive left ventricular thrombus, and bilateral chronic pulmonary emboli. Contrary to the standard indication for closure to prevent paradoxical embolism, the patient underwent balloon dilation of the PFO to 6.5 mm, along with balloon pulmonary angioplasty (BPA), to treat the thromboembolic disease. Results: The patient experienced rapid symptom relief following the procedure. At the 1-month follow-up, his HF functional class improved from NYHA IV to II, with LVEF increasing to 46.6%. At the latest follow-up (33 months), the PFO remained patent, LAP had normalized (average E/e' 8.8), the ventricular thrombus had regressed, and no further thromboembolic events had occurred. Conclusion: In patients with a PFO complicated by severe left-sided HF and elevated LAP, maintaining an interatrial shunt through balloon dilation, rather than performing PFO closure, can be a feasible and effective therapeutic strategy for improving hemodynamics and clinical status. This case highlights the necessity of individualized management in patients with complex cardiopulmonary disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.